MAJOR ARTICLE

Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial

Dafna Yahav,[1,2] Erica Franceschini,[3] Fidi Koppel,[4] Adi Turjeman,[2,5] Tanya Babich,[2,5] Roni Bitterman,[4] Ami Neuberger,[4,6] Nesrin Ghanem-Zoubi,[4] Antonella Santoro,[3] Noa Eliakim-Raz,[1,2] Barak Pertzov,[5] Tali Steinmetz,[5] Anat Stern,[4] Yaakov Dickstein,[4] Elias Maroun,[4] Hiba Zayyad,[4] Jihad Bishara,[1,2] Danny Alon,[7] Yonatan Edel,[2,8] Elad Goldberg,[9] Claudia Venturelli,[3] Cristina Mussini,[3] Leonard Leibovici,[2,5] Mical Paul,[4,6]; for the Bacteremia Duration Study Group[a]

[1]Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, and [2]Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; [3]Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy; [4]Infectious Diseases Institute, Rambam Health Care Campus, Haifa, [5]Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, [6]The Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, and [7]Department of Medicine B, [8]Department of Medicine C, and [9]Department of Medicine F, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

(See the Editorial Commentary by Daneman and Fowler on pages 1099–100.)

Background. Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited.

Methods. This was a randomized, multicenter, open-label, noninferiority trial. Inpatients with gram-negative bacteremia, who were afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 days (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative, or distant complications; and readmission or extended hospitalization (>14 days). The noninferiority margin was set at 10%.

Results. We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in 3 centers in Israel and Italy. The source of the infection was urinary in 411 of 604 patients (68%); causative pathogens were mainly Enterobacteriaceae (543/604 [90%]). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140 of 306 patients (45.8%) in the 7-day group vs 144 of 298 (48.3%) in the 14-day group (risk difference, –2.6% [95% confidence interval, –10.5% to 5.3%]). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short-course therapy arm.

Conclusions. In patients hospitalized with gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was noninferior to 14 days. Reducing antibiotic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention.

Clinical Trials Registration. NCT01737320.

Keywords. duration; bacteremia; gram-negative; antibiotics.

Shortening the duration of antibiotic therapy is an important strategy for reducing unnecessary antibiotic use in the hospital setting, where antibiotic pressure is the most intense [1]. Shorter courses of antibiotics may reduce drug-related adverse events, duration of hospitalization, emergence of

antibacterial resistance, and superinfections, including fungal and *Clostridium difficile* infections [2].

Several randomized controlled trials (RCTs) demonstrated no significant difference between short and long antibiotic courses in the treatment of mainly gram-negative infections such as pyelonephritis [3] and complicated intra-abdominal infections [4, 5]. However, patients with bacteremia were rarely enrolled in these trials. A meta-analysis of mostly nonrandomized studies demonstrated no significant difference in the outcome of 155 patients with bloodstream infections treated with short vs long antibiotic courses [6]. A recent pilot RCT randomized 115 critically ill patients with gram-negative bacteremia to 7 vs 14 days of antibiotics, but reported only on feasibility and patients' characteristics [7].

Gram-negative bacteremia is frequent with pyelonephritis, occurring in 10%–60% of patients [8], and intra-abdominal infections (<10% to 75% of patients depending on the type of

infection) and represents the more severe end of the spectrum of illness [9]. The lack of data on the appropriate treatment duration for this subset of patient leads to uncertainty, usually resolved by prolonged treatment durations [10]. Current guidelines recommend a wide range of antibiotic treatment duration between 7 and 14 days [11].

Given the limited evidence available to guide the duration of antibiotic therapy in gram-negative bacteremia, this randomized trial was designed to test the hypothesis that short-course (7 days) antibiotic therapy for gram-negative bacteremia in hospitalized patients is noninferior to a long course (14 days).

METHODS

Study Design

This was an open-label/analyst-blinded noninferiority, 1:1 parallel-group RCT conducted between 1 January 2013 and 31 August 2017 in 2 academic centers in Israel and between 1 November 2015 and 31 August 2017 in 1 academic center in Italy, with follow-up completed in November 2017. The study was approved by the local ethics board of each participating center. The study was registered at ClinicalTrials.gov (identifier NCT01737320).

Participants

We included hospitalized adult patients with aerobic gram-negative bacteremia at day 7 of covering antibiotic therapy, if hemodynamically stable and afebrile for at least 48 hours. Patients achieving clinical stability and planned for discharge before day 7 could be recruited before discharge. Patients with urinary tract, intra-abdominal, respiratory tract, central venous catheter, or skin and soft tissue infection or an unknown source of bacteremia were eligible for inclusion whether the infection was community or hospital acquired. Patients with other sources of infection, uncontrolled focus of infection, polymicrobial growth, specific pathogens (*Brucella*, *Salmonella*), or immunosuppression (neutropenia at time of randomization, human immunodeficiency virus, recent allogeneic stem cell transplantation) were excluded. A complete list of the inclusion and exclusion criteria is provided in the Supplementary Data. All participants (or an authorized proxy) provided written informed consent before randomization.

Randomization and Treatment

Patients were randomly assigned to short-course (7 days) or long-course (14 days) antibiotic therapy, counting from the first day of covering antibiotics, whether empirical or directed. Covering antibiotic therapy was defined as that matching the in vitro susceptibility of the gram-negative pathogen in blood. Empirical treatment was defined as that given before reporting of pathogen identification and susceptibility, whereas directed treatment was tailored to the final microbiological results. The type of empirical or directed antibiotic treatment was chosen by the treating physicians. The decision on timing of switch to oral antibiotic therapy as well as time of discharge was also left to the discretion of the treating physician.

Randomization was performed using a computer-generated list of random numbers in a 1:1 ratio, without blocking or stratification, and was concealed using sealed opaque envelopes prepared centrally and opened consecutively after patient recruitment in each site. Blinding was not performed due to practical limitations.

Outcomes

The primary outcome at 90 days from randomization was a composite of all-cause mortality; clinical failure, including either relapse of the bacteremia, local suppurative complications, or distant complications; and readmission or extended hospital stay (>14 days). Readmission was defined as any hospitalization occurring after discharge in both groups; hospital stay was defined as extended for any patient who continued hospitalization after day 14. Secondary outcomes included individual components of the primary outcome; development of new clinically or microbiologically documented infection by 90 days; functional capacity at day 30 and time to return to baseline activity by day 90; total hospital days among survivors and among all patients by 90 days; total antibiotic days by 90 days and duration of appropriate antibiotic treatment for the gram-negative bacteremias; development of resistance, defined as secondary clinical isolates resistant to 1 or more of the antibiotics used to treat the index gram-negative bacteremia; and adverse events, including *C. difficile* infection. Detailed definitions of the outcomes are provided in the Supplementary Data. Outcome data following discharge were collected through telephone interviews at day 30 and 90 after randomization, supplemented by access to national or regional healthcare databases.

Statistical Analysis

We aimed to include 600 patients for a primary outcome event of 35% in the control and intervention groups. Originally, we planned to enroll 400 patients and assess all-cause mortality, clinical failure (as currently defined), and development of new clinically or microbiologically documented infection as primary outcome. Safety monitoring was conducted by an independent monitoring committee following completion of the follow-up of every 150 patients. After the second safety monitoring, the committee remarked on a lower-than-expected outcome event rate. We reconsidered the patient-relevant outcomes among the bacteremia survivors achieving rapid clinical cure, defined the final composite primary outcome, and increased the target sample size to 600 patients. The study was designed to have 80% power with a 10% α-risk to exclude the noninferiority of short-course to long-course antibiotic therapy with a 10% noninferiority margin. A 10% noninferiority margin was chosen based on the US Food and Drug Administration's recommendation

for trials assessing drugs for complicated urinary tract infection (UTI) [12], considering this clinically acceptable for the population and outcome assessed in our trial and the ecological gain of reducing antibiotic use.

The primary analysis was performed by intention to treat including all patients randomized. We planned a per-protocol analysis for the primary outcome, including patients treated with appropriate antibiotics for the allocated treatment duration ±2 days (ie, 5–9 days vs 12–16 days). Prespecified subgroups for analyses of the primary outcome included patients receiving covering (appropriate) vs noncovering (inappropriate) empirical antibiotics, patients with UTI or other source of the bacteremia, and patients with gram-negative bacteremia caused by multidrug-resistant (MDR) gram-negative bacteria vs non-MDR bacteria. Definitions of multidrug resistance are provided in the Supplementary Data.

Outcome variables were compared using the χ^2 test or Fisher exact test for categorical variables and the Mann-Whitney U test for continuous variables. Results are reported using risk difference (RD) and 95% confidence intervals (CIs), calculated using the Wald method. Analyses were performed with SPSS software version 24.

RESULTS

Of 4807 patients with gram-negative bacteremia surviving to day 7, 2169 potentially eligible patients were assessed and 604 patients were included (306 in the short-duration arm and 298 in the long-duration arm) between 1 January 2013 and 31 August 2017 (Figure 1). Ninety-day follow-up for the primary outcome was completed for all patients. Overall, baseline characteristics of included patients were balanced between study arms (Table 1). The main source of bacteremia was the urinary tract (411/604 [68%]), and the main pathogens were Enterobacteriaceae (543/604 [89.9%]). Characteristics of the antibiotics prescribed were also balanced between groups, including type of antibiotics and manner of administration (intravenous/oral) (Supplementary Table 1).

The primary composite outcome of mortality, clinical failure, readmissions, or extended hospitalization at 90 days occurred in 140 of 306 patients in the short-duration group (45.8%) compared with 144 of 298 in the long-duration group (48.3%) (RD, −2.6% [95% CI, −10.5% to 5.3%]), establishing noninferiority. In a stratified analysis by the study centers, weighted by inverse variance, results were similar (RD, −2.7% [95% CI, −10.7% to 5.2%]). No significant differences between study groups were demonstrated for any of the individual primary outcome components (Table 2), including 90-day all-cause mortality, with 36 (11.8%) deaths in the short-duration group and 32 (10.7) deaths in the long-duration group (RD, 1.0% [95% CI, −4.0% to 6.1%]).

Overall, 556 patients (92%) received the protocol-specified duration ±2 days and were included in the per-protocol analysis. For the per-protocol population, the composite primary outcome occurred in 128 of 280 (45.7%) patients in the short duration group compared with 132 of 276 (47.8%) in the long duration group (RD, −2.1% [95% CI, −10.4% to 6.2%]).

The primary outcome in prespecified subgroups is shown in Figure 2. No significant difference between study arms was documented for all predefined subgroups. Noninferiority criteria were met in all subgroups, except for the subgroups that were small: patients receiving inappropriate empirical antibiotic treatment and those with bacteremia caused by a MDR pathogen.

In a post hoc analysis, there was no mortality difference between groups at 14 and 28 days; no complications or relapses were observed between 7 and 14 days. No significant difference between study groups was demonstrated for most of the secondary outcomes, including development of new clinically or microbiologically documented infections in 70 (22.9%) patients in the short treatment group vs 68 (22.8%) patients in the long treatment group (RD, 0.06 % [95% CI, −6.6% to 6.8%]) and development of resistance observed overall in 62 (10.3%) patients (RD, 1.0% [95% CI, −3.7% to 5.9%]). The total days in hospital was also similar between study arms (Table 2).

Time to return to baseline activity within 90 days was significantly shorter in the short-duration arm (median, 2 weeks [interquartile range {IQR}, 0–8.3 weeks] vs 3 weeks [IQR, 1–12 weeks]). Duration of appropriate covering antibiotic treatment for the index bacteremia was compatible with assignment (median, 7.0 days [IQR, 7.0–8.0 days] in the 7-day arm vs 14.0 days [IQR, 14.0–14.0 days] in the 14-day arm). Total antibiotic days from culture collection to 90 days from randomization was significantly less in the short-duration arm (median, 10 days [IQR, 9–18 days] vs 16 days [IQR, 15–22 days] in the 14-day arm) (Table 2).

Adverse events, including acute kidney injury, liver function test abnormalities, rash, and diarrhea were reported, with no significant differences between study groups (Table 2). *Clostridium difficile* infection was documented in 4 patients overall.

DISCUSSION

In this RCT including hospitalized patients with gram-negative bacteremia, hemodynamically stable by day 7, we found 7 days of antibiotic therapy to be noninferior to 14 days in terms of mortality, clinical failure, readmissions, and prolonged hospitalization. A difference in the median antibiotic treatment duration of 7 days between treatment groups was maintained until day 90. Duration of hospitalization, rates of superinfections, development of resistance, and adverse events were not significantly different between 7 and 14 days. Subgroup analysis demonstrated no significant difference between the 7-day and 14-day groups for the composite primary outcome in patients with UTI, patients receiving inappropriate empirical therapy, and patients with MDR pathogens (mostly extended-spectrum β-lactamase [ESBL]). Adherence to the allocated regimen was good, with 556 patients (92%) receiving the preplanned

```
┌─────────────────────────────────────┐
│ Patients with Gram-negative bacteremia │
│   screened for the trial ᵃ (n=4807)   │
└─────────────────────────────────────┘
```

Non-eligible
- Specific pathogen excluded (=55)
- Polymicrobial growth (n=557)
- Immunosuppression (n=365)
- Repeated positive blood cultures (n=96)
- Hemodynamic instability or fever 48 h prior to randomization day (n=653)
- Uncontrolled focus of infection (n=912)

Assessed for eligibility (n=2169)

Excluded (n=1565)
- Previous enrollment in this trial (n=13)
- Participation in another clinical trial (n=169)
- Special population (n=53)
- Patient/ guardian refusal (n=370)
- Unable to provide informed consent (n=810)
- Treating physician unwillingness (n=150)

604 patients were enrolled and underwent randomization

Allocated to intervention (n=306)
♦ Received allocated 7 days (n=280)
♦ Did not receive 7 days (n=26)
 Treatment prolonged (n=26)

Allocated to control (n=298)
♦ Received 14 days (n=276)
♦ Did not receive 14 days (n=22)
 Treatment prolonged (n=9)
 Treatment shortened (n=13)

Lost to follow-up (n=0)

Discontinued intervention (n=0)

Lost to follow-up (n=0)

Discontinued intervention – treatment shortened due to:

Death (n=1); patient decision (n=1); physician decision (n=1)

Analysed (n=280)
♦ Excluded from per protocol analysis (n=26)

Analysed (n=276)
♦ Excluded from per protocol analysis (n=22)

ᵃ All patients with Gram-negative bacteremia during the study period, surviving to day 7 and not discharged before recruitment

Figure 1. Trial flowchart. ᵃAll patients with gram-negative bacteremia during the study period, surviving to day 7, and not discharged before recruitment.

allocated duration ±2 days. No significant difference in the composite primary outcome was demonstrated between study arms in the per-protocol population.

Limited data are available to support the optimal duration of antibiotic therapy for gram-negative bacteremia. A few retrospective, propensity score–matched cohort studies have addressed this issue in recent years, showing conflicting results. Chotiprasitsakul et al compared 6–10 days vs 11–16 days for the treatment of Enterobacteriaceae bloodstream infections

and showed no difference in 30-day mortality or relapse between treatment groups, with a trend toward less emergence of resistance in the 6- to 10-day treatment group [13]. Park et al conducted a similar study in children and demonstrated no difference in 30-day mortality or relapse and a trend toward higher risk of candidemia with treatment duration of >10 days [14]. Similar results were also demonstrated in patients with *Escherichia coli* bacteremia [15]. In contrast, Nelson et al found higher rates of treatment failure using <10 days of antibiotics

Table 1. Baseline Characteristics of Included Patients

Variable	Short-duration Arm (7 d) (n = 306)	Long-duration Arm (14 d) (n = 298)
Patient characteristics		
Age, y, median (IQR)	71 (61.8–81)	71 (61–80)
Sex, female	156 (51.0)	163 (54.7)
Center		
Rambam Hospital, Israel	133 (43.5)	118 (39.6)
Beilinson Hospital, Israel	131 (42.8)	143 (48.0)
Hospital of Modena, Italy	42 (13.7)	37 (12.4)
Charlson comorbidity score, median (IQR)	2 (1–3)	2 (1–4)
Malignancy		
None	222 (72.5)	223 (74.8)
Solid	64 (20.9)	58 (19.5)
Hematological	20 (6.5)	17 (5.7)
Immunosuppression[a]		
Any	69 (22.5)	81 (27.2)
Solid organ transplantation	25 (8.2)	26 (8.7)
Stem cell transplantation	2 (0.7)	3 (1.0)
Functional capacity		
Independent	186 (61.1)	189 (63.4)
Needs assistance in ADL	53 (17.3)	44 (14.8)
Dependent in ADL	40 (13.1)	51 (17.1)
Bedridden	26 (8.5)	14 (4.7)
Devices at baseline		
Urinary device[b]	61 (19.9)	72 (24.2)
Central venous catheter	22 (7.2)	19 (6.4)
Endotracheal tube	8 (2.6)	8 (2.7)
Prosthetic valve/intracardiac implantable device	14 (4.6)	13 (4.4)
Infection characteristics		
Hospital-acquired infection	81 (26.5)	95 (31.9)
Presentation of infection		
SOFA score at presentation, median (IQR)	2 (1–3)	2 (1–3)
Leukocytes at presentation, cells/μL, median (IQR)	10.6 (7.4–15.4) (n = 306)	11.3 (7.8–15.2) (n = 297)
Creatinine at presentation, mg/dL, median (IQR)	1.2 (0.9–1.7) (n = 304)	1.3 (0.8–1.8) (n = 297)
Albumin at presentation, g/dL, median (IQR)	3.3 (2.7–3.8) (n = 195)	3.3 (2.9–3.8) (n = 197)
SOFA score at randomization, median (IQR)	1 (0–2)	1 (0–2)
Systolic blood pressure at randomization, mm Hg, median (IQR)	128.0 (115.0–144.3)	126.0 (110.0–140.0)
Temperature at randomization, °C, median (IQR)	36.8 (36.6–37.1) (n = 304)	36.8 (36.6–37.0) (n = 298)
Appropriate empirical therapy administered within 48 h	260 (85.0)	242 (81.2)
Bacteria type[c]		
Escherichia coli	186 (60.8)	194 (65.1)
Klebsiella spp	47 (15.3)	33 (11.1)
Other Enterobacteriaceae	40 (13.1)	43 (14.4)
Acinetobacter spp	2 (0.7)	4 (1.3)
Pseudomonas spp	28 (9.2)	20 (6.7)
Other	3 (1)	4 (1.3)
MDR gram-negative bacteremia[d]	58 (18.9)	51 (17.1)
Source of bacteremia		
Urinary tract	212 (69.3)	199 (66.8)
Primary bacteremia	23 (7.5)	28 (9.4)
Abdominal	37 (12.1)	34 (11.4)
Respiratory	14 (4.6)	10 (3.4)
Central venous catheter	15 (4.9)	23 (7.7)
Skin and soft tissue	5 (1.6)	4 (1.3)

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: ADL, activities of daily living; IQR, interquartile range; MDR, multidrug-resistant; SOFA, Sequential Organ Failure Assessment.

[a]Immunosuppression indicates any immunosuppressive drugs, including prednisone ≥20 mg/day or equivalent.

[b]Including urinary catheter (58/298 long-duration arm, 42/306 short-duration arm) and nephrostomy tubes or double-J catheters (14/298 long-duration arm, 19/306 short-duration arm).

Table 2. Outcomes of 7 Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia

Outcome	Short Arm (7 d) (n = 306)	Long Arm (14 d) (n = 298)	Risk Difference (95% CI)	P Value
Primary outcome	140 (45.8)	144 (48.3)	−2.6 (−10.5 to 5.3)	.527
90-d all-cause mortality	36 (11.8)	32 (10.7)	1.0 (−4.0 to 6.1)	.702
Readmissions	119 (38.9)	127 (42.6)	−3.7 (−11.5 to 4.1)	.363
Extended hospitalization beyond 14 d	15 (4.9)	19 (6.4)	−1.5 (−5.1 to 2.2)	.483
Distant complications	2 (0.7)	1 (0.3)	…	1.0
Relapse of bacteremia	8 (2.6)	8 (2.7)	−0.07 (−2.6 to 2.5)	.957
Suppurative complications	16 (5.2)	10 (3.4)	1.8 (−1.4 to 5.1)	.257
14-d mortality	7 (2.3)	4 (1.3)	0.95 (−1.42 to 3.44)	.288
28-d mortality	15 (4.9)	13 (4.4)	0.54 (−2.98 to 4.06)	.753
New clinically or microbiologically documented infection	70 (22.9)	68 (22.8)	0.06 (−6.6 to 6.8)	.987
Functional capacity: needs assistance/dependent in ADL or bedridden at 30 d	150 (51.4) (n = 292)	163 (57.2) (n = 285)	−5.8 (−13.9 to 2.3)	.031
Resistance development	33 (10.8)	29 (9.7)	1.0 (−3.7 to 5.9)	.690
Time to return to baseline activity, wk (90 d)	2 (0–8.3) (n = 218)	3 (1–12) (n = 222)	…	**.010**
Total hospital days (90 d from randomization)—survivors	3 (1–9) (n = 270 alive at day 90)	3.5 (1–10) (n = 266 alive at day 90)	…	.923
Total hospital days (90 d from randomization)—all	4 (1–10)	4 (1–12)	…	.603
Duration of appropriate antibiotic therapy for bacteremia	7 (7.0–8.0)	14.0 (14.0–14.0)	…	**< .001**
Total antibiotic days from culture collection to day 90 postrandomization	10.0 (9.0–18.0) (n = 270 alive at day 90)	16.0 (15.0–22.0) (n = 266 alive at day 90)	…	**< .001**
Adverse events				
Acute kidney injury	14 (4.6)	12 (4.0)	0.5 (−2.7 to 3.8)	.842
Liver function abnormalities	16 (5.2)	20 (6.7)	−1.5 (−5.3 to 2.3)	.494
Diarrhea during hospital stay	17 (5.6)	23 (7.7)	−2.2 (−6.1 to 1.8)	.285
Diarrhea until day 90[a]	49 (16)	54 (18.1)	−2.1 (−8.1 to 3.9)	.491
Rash	2 (0.7)	4 (1.4)	…	.445
Clostridium difficile infection	3 (1.0)	1 (0.3)	…	.322

Data are presented as no. (%) unless otherwise indicated. Values in bold indicate statistically significant difference.

Abbreviations: ADL, activities of daily living; CI, confidence interval.

[a]Diarrhea is defined as ≥3 episodes per day for at least 2 days.

for gram-negative bacteremia in adults, including the subgroup of patients with UTI [16, 17]. This study assessed death or infection relapse after discharge among patients with gram-negative bacteremia who were discharged alive after the bacteremia and without an extended hospitalization. Excluding extended hospitalization and readmissions from our primary outcome results in an outcome defined similarly to the one reported by Nelson et al (death, relapse, or bloodstream-related complications), but in our RCT there was no significant difference between groups (57 of 306 [18.6%] with short-course therapy vs 45 of 298 [15.1%] with long-course therapy; RD, 3.53% [95% CI, −2.48% to 9.49%]). In an ongoing similar trial conducted in intensive care units (Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness [BALANCE]) [18], the aim is to show noninferiority with respect to 90-day survival with

a noninferiority margin of 4%; our trial nearly achieves this aim as well (RD for 90-day mortality, −1.03% [95% CI, −6.06% to 4.01%]). Judging by the high adherence to the study protocol in our trial and in a report of a pilot study preceding the BALANCE trial [9], short-duration treatment is acceptable to both physicians and patients.

Functional decline is well described following sepsis, although few data addressing predictors of return to baseline capacity are available. It is probably the most significant adverse consequence among elderly survivors of sepsis [19]. In the current study, a more rapid return to baseline activity was documented for the short-duration antibiotic arm. This occurred despite the lack of superiority of other outcomes. Functional capacity was assessed as the patient's subjective assessment of her/his performance relative to the baseline before

Table 1. Continued

cSixteen patients with bloodstream infection with Enterobacteriaceae had a polymicrobial infection (7 patients in the short-duration arm and 9 patients in the long-duration arm had 7 and 11 isolates, respectively). Of these 16 patients, 11 had another Enterobacteriaceae as a co-pathogen, and 5 had a different gram-negative pathogen as the co-pathogen (3 *Aeromonas* spp [2 short-duration arm, 1 long-duration arm] and 2 *Pseudomonas* spp [1 in each arm]). Other gram-negative bacteria included 1 *Stenotrophomonas maltophilia*, 1 *Chryseobacterium meningosepticum*, 1 *Haemophilus influenzae*, and 1 *Aeromonas* spp in the long-duration arm; and 1 *Stenotrophomonas maltophilia*, 1 other nonfermenter, and 1 *Aeromonas* spp in the short-duration arm.

dMDR pathogens: extended-spectrum β-lactamase (ESBL), 56 of 273 (20.5%) Enterobacteriaceae in the short-duration arm vs 49 of 270 Enterobacteriaceae (18.1%) in the long-duration arm. MDR nonfermenters, 1 *Pseudomonas aeruginosa* and 1 *Acinetobacter baumannii* in the short-duration arm (2/33 [6.1%] nonfermenters) vs 1 *Pseudomonas aeruginosa* and 1 *Chryseobacterium meningosepticum* in the long-duration arm (2/28 [7.1%] nonfermenters). For definitions of ESBL and MDR, see the Supplementary Data.

| Subgroup | Short | | Long | | Risk Difference | Risk Difference |
	Events	Total	Events	Total	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
.1 Bacteremia source						
UTI	92	212	88	199	-0.01 [-0.10, 0.09]	
non-UTI	48	94	56	99	-0.06 [-0.20, 0.09]	
.2 Empirical antibiotic treatment						
Covering empirical	112	260	109	242	-0.02 [-0.11, 0.07]	
Non-covering empirical	28	46	35	56	-0.02 [-0.21, 0.17]	
.3 Multi-drug resistance						
MDR	39	58	34	51	0.01 [-0.17, 0.18]	
Non-MDR	101	248	110	247	-0.04 [-0.13, 0.05]	

Favours short treatment   Favours long treatment

UTI – urinary tract infection

Empirical antibiotic treatment – covering antibiotics to the specific pathogen according to

susceptibility pattern administered within 48 hours

MDR – Multidrug resistance. This subgroup includes 105 patients with an ESBL

Enterobacteriaceae and 4 additional patients with another MDR bacteria (2 *Pseudomonas*

aeruginosa, one *Acinetobacter baumannii* and one *Chryseobacterium meningosepticum*)

Figure 2. Primary outcome according to patient subgroups. Empirical antibiotic treatment indicates covering antibiotics to the specific pathogen according to susceptibility pattern administered within 48 hours. The multidrug-resistant (MDR) subgroup includes 105 patients with an extended-spectrum β-lactamase Enterobacteriaceae and 4 additional patients with another MDR bacteria (2 *Pseudomonas aeruginosa*, 1 *Acinetobacter baumannii*, and 1 *Chryseobacterium meningosepticum*). Abbreviations: CI, confidence interval; MDR, multidrug-resistant; M–H, Mantel–Haenszel; UTI, urinary tract infection.

the bacteremia. The perception of illness while taking antibiotics might have biased this outcome in favor of the short-course treatment. However, we believe this bias reflects a true advantage to short-course treatment with respect to patients' perception of well-being and functional performance. Adverse events that were not captured might have occurred, explaining this difference.

Shortening antibiotic treatment is expected to result in fewer adverse events, mainly antibiotic-associated diarrhea and *C. difficile* infection. The finding of fewer antibiotic days during the 3 months following randomization in the short-duration arm was not reflected in these outcomes in our trial. This could possibly be explained by low rates of *C. difficile* infection and other adverse events in our patients. The main spur for shortening antibiotic treatment duration is the basic assumption that shorter duration will reduce resistance selection and development. In our trial, this was assessed through monitoring of secondary infections caused by bacteria resistant to the antibiotics used for the index bacteremia, and we did not detect an advantage to the shorter treatment. This could have occurred as we did not monitor for ESBLs or other resistant bacteria uniformly in both groups and because we did not perform surveillance sampling for colonization by such bacteria. However, the timescale of development and spread of resistance are not compatible with that of an RCT. These outcomes should be assessed on a longer timescale within a setting (hospital, unit) in which antibiotic treatment duration is shortened as a policy.

There are several strengths and limitations to this study. Our study is the first RCT assessing antibiotic duration in gram-negative bacteremia. Strengths of the trial, in addition to its design, are the nonrestrictive inclusion criteria allowing a representative cohort of eligible patients, including a large population of elderly patients (aged ≥65 years; 404/604 [66.9%]) and immunocompromised patients (150/604 [24.8%], mainly solid organ transplant recipients and patients treated for malignancy). However, this trial's cohort is not comparable to other bacteremia cohorts, as it starts from 7-day survivors of gram-negative bacteremia achieving hemodynamic stability for at least 48 hours before day 7 with no uncontrolled source of infection. Its results are valid for these patients. Our primary outcome is composed of the outcomes relevant to early survivors of bacteremia, namely long-term survival, without complications and discharged from hospital. Among secondary outcomes, we considered all those later suggested for the Desirability of Outcome Ranking and Response Adjusted for Duration of Antibiotic Risk (DOOR/RADAR), including functional capacity and exposure to antibiotics [20].

Limitations include the dominance of Enterobacteriaceae as the offending pathogens (~90%), which limits the applicability of the results for gram-negative nonfermenters such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. We could not show the impact of reducing antibiotic use on resistance. The potential of shorter antibiotic courses to shorten the length of hospital stay was not fully realized in our trial,

as patients in the long-duration arm could complete therapy as outpatients using highly absorbable antibiotics such as quinolones. Including readmissions and extended hospitalization in the primary outcome might have favored noninferiority.

In summary, among hospitalized patients with gram-negative bacteremia who were hemodynamically stable and afebrile for at least 48 hours without an ongoing focus of infection, 7 days of antibiotic therapy was noninferior to 14 days. Seven days of antibiotic therapy had the advantage of fewer cumulative antibiotic days within 3 months and more rapid regain of baseline functional capacity.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

References

1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011; 52:1232–40.
2. Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents 2009; 34(Suppl 4):S47–51.
3. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68:2183–91.
4. Royer S, DeMerle KM, Dickson RP, Prescott HC. Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis. J Hosp Med 2018; 13:336–42.
5. Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015; 372:1996–2005.
6. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011; 15:R267.
7. Daneman N, Rishu AH, Pinto R, et al; Canadian Critical Care Trials Group. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials 2018; 19:111.
8. Karakonstantis S, Kalemaki D. Blood culture useful only in selected patients with urinary tract infections—a literature review. Infect Dis (Lond) 2018; 50:584–92.
9. Mandell GB, J. Dolin, R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders, 2015.
10. Daneman N, Rishu AH, Xiong W, et al; Canadian Critical Care Trials Group. Duration of antimicrobial treatment for bacteremia in Canadian critically ill patients. Crit Care Med 2016; 44:256–64.
11. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1–45.
12. US Food and Drug Administration, Center for Drug Evaluation and Research. Complicated urinary tract infections: developing drugs for treatment guidance for industry. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070981.pdf. Accessed 11 September 2018.
13. Chotiprasitsakul D, Han JH, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis 2018; 66:172–7.
14. Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated gram-negative bacteraemia. J Antimicrob Chemother 2014; 69:779–85.
15. Giannella M, Pascale R, Toschi A, et al. Treatment duration for *Escherichia coli* bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect 2018; 24:1077–83.
16. Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal duration of antimicrobial therapy for uncomplicated gram-negative bloodstream infections. Infection 2017; 45:613–20.
17. Al-Hasan MN, Nelson AN, Justo JA, Albrecht H, Kohn J, Brandon Bookstaver P. Reply to comments: duration of antimicrobial therapy for gram-negative bacteremia secondary to urinary source of infection. Infection 2018; 46:283–4.
18. Daneman N, Rishu AH, Xiong W, et al; Canadian Critical Care Trials Group. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials 2015; 16:173.
19. Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect 2013; 19:510–2.
20. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015; 61:800–6.